Refining cPRA calculation to improve HLA compatibility assessment in organ transplantation: A detailed picture of the Paris waiting list
HLA · 2024
DOI: 10.1111/tan.15675 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2024. Verfasst von Cédric Usureau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France. Hauptthemen laut MEDLINE: Histocompatibility Testing, HLA Antigens, Waiting Lists, Isoantibodies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Direction Générale de l'Offre de Soins, project PHRC-N ACORGHLA AAP2016 NCTT03861962.
Abstract (Originalsprache)
The determination of panel reactive antibodies (cPRA) scores plays a critical role in assessing the immunological compatibility between organ transplant recipients and potential donors. Traditional cPRA methods focus on a limited number of HLA loci using physical cytotoxicity tests. However, advancements such as the Luminex single antigen (LSA) assay, which uses mean fluorescence intensity (MFI) of individualised HLA antigens for antibody evaluation, provide a foundation for a more precise assessment. We developed cPRAdictor, a novel cPRA calculation tool using a large series of HLA‐type individuals in France with NGS. cPRAdictor was applied to a cohort of 5962 kidney transplant candidates in Paris. We analysed how extending the range of HLA specificities could affect cPRA values. Implementing cPRAdictor revealed and allowed quantification of the significant discrepancies in cPRA values that appeared when HLA loci C and DP, and antigen‐specific antibodies were taken into account. Notably, over 43% of the immunised transplant candidates showed an increase in calculated cPRA values when considering C/DP loci and antigen‐specific antibodies, negatively impacting their eligibility and prioritisation in the transplantation programme. These findings highlight the necessity of revisiting cPRA calculation methodologies to include a broader spectrum of immunological data, as more exhaustive and precise information regarding anti‐HLA antibodies in patients' sera and donor and recipient HLA typing are available prospectively. This will strongly improve both accuracy and equity at the organ allocation step, especially for highly sensitised candidates for whom organ offers are very limited in number.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France.
- INSERM UMR976, Institut de Recherche Saint-Louis, Université de Paris-Cité, Paris, France.
- MICS-Research Laboratory in Mathematics and Computer Science, Centrale Supélec, Paris-Saclay University, Gif-Sur-Yvette, France.
ORCID-Profile: Cédric Usureau, Romain Lhotte, Valentin Clichet, Magali Devriese, Jean-Luc Taupin
Förderung
- Direction Générale de l'Offre de Soins, project PHRC-N ACORGHLA AAP2016 NCTT03861962
Zitieren
APA
Usureau, C., Lhotte, R., Clichet, V., Foroutan, A., Devriese, M., & Taupin, J. L. (2024). Refining cPRA calculation to improve HLA compatibility assessment in organ transplantation: A detailed picture of the Paris waiting list. HLA. https://doi.org/10.1111/tan.15675
Vancouver
Usureau C, Lhotte R, Clichet V, Foroutan A, Devriese M, Taupin JL. Refining cPRA calculation to improve HLA compatibility assessment in organ transplantation: A detailed picture of the Paris waiting list. HLA. 2024. doi:10.1111/tan.15675
BibTeX
@article{Usureau2024,
author = {Usureau, Cédric and Lhotte, Romain and Clichet, Valentin and Foroutan, Alexandre and Devriese, Magali and Taupin, Jean-Luc},
title = {Refining cPRA calculation to improve HLA compatibility assessment in organ transplantation: A detailed picture of the Paris waiting list},
journal = {HLA},
year = {2024},
doi = {10.1111/tan.15675}
}
EUVIMED